Melanotan II vs GHK-Cu.

Melanotan II (MT-II) is a synthetic, cyclic heptapeptide analog of the natural hormone alpha-melanocyte-stimulating hormone (alpha-MSH). It was developed at the University of Arizona in the late 1980s and 1990s as part of a program designing protease-resistant "superpotent" melanotropins; the related linear analog melanotan I became the approved drug afamelanotide (Scenesse). Unlike afamelanotide, Melanotan II itself was never approved as a medicine and today circulates almost exclusively as an unlicensed product sold online for cosmetic "tanning" and as a libido agent.

GHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide with the sequence glycyl-L-histidyl-L-lysine. GHK was first isolated from human plasma by Loren Pickart in the early 1970s and also occurs in saliva and urine; it binds copper ions with high affinity to form the violet-colored GHK-Cu complex. The free peptide sequence is embedded within the alpha-2 chain of type I collagen, and it is thought to be liberated during tissue injury, making it a candidate endogenous signal of tissue damage and repair. It is best known as a cosmetic ingredient and a widely studied "copper peptide."

Melanotan II is a non-selective agonist of the melanocortin receptor family, binding MC1R, MC3R, MC4R and MC5R rather than selectively targeting MC1R. Activation of MC1R on cutaneous melanocytes stimulates the cAMP pathway and shifts melanin synthesis toward darker eumelanin, producing skin darkening that, unlike a UV tan, can occur with reduced sun exposure. Its central effects on sexual arousal and appetite are attributed mainly to MC4R (with possible MC3R contribution) in the hypothalamus and related circuits, while nausea, flushing and yawning also arise from this broad central melanocortin activation. The cyclic lactam structure makes it markedly more resistant to enzymatic degradation and more potent and longer-acting than native alpha-MSH.

GHK is a copper-coordinating molecule: the glycine amino terminus, the histidine imidazole, and a deprotonated peptide nitrogen form a square-planar Cu(II) chelate, a geometry confirmed by X-ray and solution-structure studies, allowing GHK to shuttle copper to and from cells and to modulate copper's redox chemistry. Beyond copper transport, GHK-Cu has been reported to stimulate fibroblast synthesis of collagen, elastin, glycosaminoglycans, and proteoglycans while modulating matrix metalloproteinases, consistent with a role in dermal remodeling. Bioinformatic analysis using the Broad Institute Connectivity Map found that GHK alters the expression of a large fraction of assayed human genes in cultured cells (upregulating some and suppressing others), including genes tied to antioxidant defense, anti-inflammatory signaling, DNA repair, and tissue regeneration. It has also shown antioxidant behavior in vitro, including blocking copper-dependent oxidation of low-density lipoprotein.

Human data on Melanotan II is limited to small, early-phase academic studies and a large body of case reports; no Phase 2/3 program was ever completed and it has never been tested in large controlled trials. The best-documented human work is on erectile function: a 1998 double-blind, placebo-controlled crossover study in men with psychogenic erectile dysfunction (Wessells et al., J Urol) and a 2000 study in men with organic erectile dysfunction (Urology) reported that subcutaneous Melanotan II initiated erections, accompanied by frequent nausea and yawning. Its tanning rationale rests on MC1R pharmacology and on the broader melanotan development program (Hadley et al., 1998), but rigorous controlled efficacy/safety data for cosmetic tanning in humans is essentially absent. Most contemporary human evidence comes from adverse-event case reports, including systemic toxicity with rhabdomyolysis (Clinical Toxicology, 2012) and dermatologic changes, so claims of benefit substantially outrun the controlled-trial evidence.

The strongest human evidence is cosmetic/dermatologic: small topical studies of GHK-Cu-containing creams have reported improvements in skin appearance, density, and wrinkles, but these are generally short, small, and often industry-adjacent rather than large randomized therapeutic trials. Much of the mechanistic case rests on in vitro and animal work (fibroblast cultures, rodent and rabbit wound-healing models, and rat nerve-regeneration experiments), plus gene-expression analyses (Pickart & Margolina, Int J Mol Sci 2018; Pickart et al., BioMed Res Int 2015). A notable bioinformatic finding is that GHK was computationally identified, via Connectivity Map screening of a human COPD lung gene signature, as a compound predicted to reverse that disease-associated expression pattern (Meiners & Eickelberg, Genome Medicine 2012), but this was a transcriptomic prediction, not a clinical trial, and GHK was not administered to patients. There are no large controlled human trials supporting injected/systemic GHK-Cu for anti-aging, organ repair, or the regenerative claims often made online; that gap between mechanistic plausibility and proven clinical benefit is wide.

Commonly reported short-term effects in humans include nausea, vomiting, facial flushing, spontaneous yawning and stretching, appetite suppression, darkening of existing moles, and spontaneous erections or priapism in men. More serious documented harms from unregulated use appear in case reports: rhabdomyolysis and systemic toxicity, and a recurring concern about changes to melanocytic naevi (new and darkening moles, atypical naevi) with multiple published cases of melanoma reported in users, though causality has not been established and confounding by concurrent UV/tanning-bed exposure is a major limitation. Because the product is unlicensed and typically self-injected from non-pharmaceutical sources, contamination, mislabeling, dosing errors and sterility problems are additional, poorly quantified risks. This entry intentionally gives no doses or protocols; anyone considering use should consult a clinician, and dermatology bodies advise against use.

In topical cosmetic use GHK-Cu has a long track record and is generally well tolerated, with the main reported issues being local irritation, redness, or contact sensitivity in some users. The safety of injected or systemic GHK-Cu in humans is not established by rigorous clinical study, and because the molecule carries copper, concerns about copper loading and pro-oxidant copper redox chemistry are biologically plausible and not well characterized for non-topical use. Purity, sterility, and actual copper content of research-grade or compounded products are unverified and vary by supplier. Overall, human safety data outside cosmetic topical contexts is thin, and unknowns dominate.

Melanotan II is not approved by the FDA or any major regulator for any indication and is not legally marketed as a medicine; products sold online are unlicensed. Regulators including the US FDA, the UK MHRA and Australia's TGA have issued consumer warnings against it. The distinct linear analog melanotan I (afamelanotide, Scenesse) is separately FDA- and EMA-approved, but only for erythropoietic protoporphyria, not for tanning.

GHK-Cu is not an FDA-approved drug; it is used as a cosmetic skincare ingredient (where cosmetic ingredients are not FDA pre-approved) and is otherwise sold for research/investigational purposes. It is not an approved therapeutic for wound healing, anti-aging, or any systemic indication, and it is not currently a WADA-prohibited substance.